Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2020

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study

(1) , (2, 3) , (4) , (5) , (3) , (6, 7) , (8) , (9) , (10) , (11) , (12) , (4) , (1, 13) , (1) , (1, 13)
1
2
3
4
5
6
7
8
9
10
11
12
13
Caroline Dutriaux
  • Fonction : Auteur
  • PersonId : 1101731
Eve Maubec
  • Fonction : Auteur
  • PersonId : 1101819
Marie-Therese Leccia
  • Fonction : Auteur
  • PersonId : 862742
Brigitte Dreno
  • Fonction : Auteur
  • PersonId : 1032931
Marie Beylot-Barry
  • Fonction : Auteur
  • PersonId : 1101824

Résumé

Despite significant progress in melanoma survival, therapeutic options are still needed in case of progression under immune checkpoint inhibitors (ICI), and resistance to targeted therapies (TT) in BRAF-mutated melanomas. This study aimed to assess the safety of combined ICI and TT as a rescue line in real-life clinical practice. We conducted a study within the prospective French multicentric MelBase cohort, including patients treated with a combination of anti-PD1 (pembrolizumab/nivolumab) and BRAF inhibitor (BRAFi: dabrafenib/vemurafenib) and/or MEK inhibitors (MEKi: trametinib/cobimetinib) for BRAF mutated or wild-type advanced melanoma. Fifty-nine patients were included: 30% received the triple combination, 34% an anti-PD1 and BRAFi, and 36% an anti-PD1 and MEKi. Grade 3–4 adverse events occurred in 12% of patients. Permanent discontinuation or dose reduction of one of the treatments for toxicity was reported in 14% and 7% of patients, respectively. In the BRAF wild-type subgroup, treatment with MEKi and anti-PD1 induced a tumor control rate of 83% and median progression-free survival of 7.1 months. The combination of anti-PD1 and BRAFi and/or MEKi was a safe rescue line for advanced melanoma patients previously treated with ICI/TT. The benefit of these combinations, specifically anti-PD1 and MEKi in BRAF wild-type melanoma patients, needs to be prospectively studied.
Fichier principal
Vignette du fichier
cancers-12-01666-v2.pdf (826.34 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03257701 , version 1 (11-06-2021)

Licence

Paternité - CC BY 4.0

Identifiants

Citer

Sandra Huynh, Laurent Mortier, Caroline Dutriaux, Eve Maubec, Marie Boileau, et al.. Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. Cancers, 2020, 12 (6), pp.1666. ⟨10.3390/cancers12061666⟩. ⟨hal-03257701⟩
41 Consultations
72 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More